keyword
MENU ▼
Read by QxMD icon Read
search

Ckd treatment

keyword
https://www.readbyqxmd.com/read/29333149/a-summary-of-worldwide-national-activities-in-chronic-kidney-disease-ckd-testing
#1
Roberto Ruiz-Arenas, Rosa Sierra-Amor, David Seccombe, Stella Raymondo, Maria Stella Graziani, Mauro Panteghini, Tewogbade A Adedeji, Shanthi Naidu Kamatham, Vanja Radišić Biljak
Chronic kidney disease (CKD) is a major public health issue worldwide and is associated with adverse health outcomes, especially in low- and middle-income countries. In a cash limited healthcare system, guidelines that improve the efficiency of health care free up resources needed for other healthcare services. This short review presents some examples from national acitivities in CKD testing, including countries throughout the globe: Mexico in North America, Uruguay in South America, Italy in Europe, Nigeria in Africa and India in Asia...
December 2017: EJIFCC
https://www.readbyqxmd.com/read/29332935/novel-treatment-strategies-for-chronic-kidney-disease-insights-from-the-animal-kingdom
#2
REVIEW
Peter Stenvinkel, Johanna Painer, Makoto Kuro-O, Miguel Lanaspa, Walter Arnold, Thomas Ruf, Paul G Shiels, Richard J Johnson
Many of the >2 million animal species that inhabit Earth have developed survival mechanisms that aid in the prevention of obesity, kidney disease, starvation, dehydration and vascular ageing; however, some animals remain susceptible to these complications. Domestic and captive wild felids, for example, show susceptibility to chronic kidney disease (CKD), potentially linked to the high protein intake of these animals. By contrast, naked mole rats are a model of longevity and are protected from extreme environmental conditions through mechanisms that provide resistance to oxidative stress...
January 15, 2018: Nature Reviews. Nephrology
https://www.readbyqxmd.com/read/29331037/pharmacist-intervention-for-blood-pressure-control-in-patients-with-diabetes-and-or-chronic-kidney-disease
#3
Maxwell D Anderegg, Tyler H Gums, Liz Uribe, Eric J MacLaughlin, James Hoehns, Oralia V Bazaldua, Timothy J Ives, David L Hahn, Christopher S Coffey, Barry L Carter
OBJECTIVES: The objectives of this study were to 1) determine if hypertensive patients with comorbid diabetes mellitus (DM) and/or chronic kidney disease (CKD) receiving a pharmacist intervention had a greater reduction in mean blood pressure (BP) and improved BP control at 9 months compared to those receiving usual care and 2) compare Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) guideline and 2014 guideline (JNC-8) BP control rates in patients with DM and/or CKD...
January 13, 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29329530/design-and-evaluation-of-a-mobile-application-to-assist-the-self-monitoring-of-the-chronic-kidney-disease-in-developing-countries
#4
Alvaro Sobrinho, Leandro Dias da Silva, Angelo Perkusich, Maria Eliete Pinheiro, Paulo Cunha
BACKGROUND: The chronic kidney disease (CKD) is a worldwide critical problem, especially in developing countries. CKD patients usually begin their treatment in advanced stages, which requires dialysis and kidney transplantation, and consequently, affects mortality rates. This issue is faced by a mobile health (mHealth) application (app) that aims to assist the early diagnosis and self-monitoring of the disease progression. METHODS: A user-centered design (UCD) approach involving health professionals (nurse and nephrologists) and target users guided the development process of the app between 2012 and 2016...
January 12, 2018: BMC Medical Informatics and Decision Making
https://www.readbyqxmd.com/read/29328026/clinical-efficacy-of-s-adenosylmethionine-in-patients-with-non-alcoholic-steatohepatitis-and-chronic-kidney-disease-i-ii-stage
#5
A Antoniv, N Antofiychuk, T Danylyshina, I Trefanenko, V Shuper
The article presents a theoretical generalization of the results of the clinical efficacy of S-adenosylmethionine in patients with non-alcoholic steatohepatitis (NASH) in comorbidity with obesity and chronic kidney disease (CKD) of the 1st-2nd stages. The objective of the article was to determine the likely effect of S-adenosylmethionine and Meldonium on the clinical course of non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD) of the I-II stages. We examined 75 patients with NASH with comorbid obesity I degree and CKD I and II dgrees...
December 2017: Georgian Medical News
https://www.readbyqxmd.com/read/29327401/daclatasvir-and-reduced-dose-sofosbuvir-an-effective-and-pangenotypic-treatment-for-hepatitis-c-in-patients-with-egfr-30-ml-min
#6
Amit Goel, Dharmendra Singh Bhadauria, Anupma Kaul, Prashant Verma, Mayank Mehrotra, Amit Gupta, Raj Kumar Sharma, Praveer Rai, Rakesh Aggarwal
BACKGROUND & AIMS: Sofosbuvir is a key agent for HCV treatment. It is not recommended for patients with chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR) <30 mL/min. We report real-life experience of treating a cohort of CKD patients with eGFR <30 mL/min using daclatasvir and half-daily dose of sofosbuvir. METHODS: Adults patients who (i) had eGFR<30 ml/min and detectable HCV RNA and (ii) were treated with interferon and ribavirin free, DAA based regimens were included...
January 12, 2018: Nephrology
https://www.readbyqxmd.com/read/29325796/lcz696-sacubitril-valsartan-an-angiotensin-receptor-neprilysin-inhibitor-attenuates-cardiac-hypertrophy-fibrosis-and-vasculopathy-in-a-rat-model-of-chronic-kidney-disease
#7
Yasunori Suematsu, Wanghui Jing, Ane Nunes, Moti L Kashyap, Mahyar Khazaeli, Nosratola D Vaziri, Hamid Moradi
BACKGROUND: Chronic kidney disease (CKD) is associated with cardiac hypertrophy, fibrosis and increased risk of cardiovascular mortality. LCZ696 (Sacubitril/valsartan) is a promising agent which has shown significant potential in treatment of heart failure. We hypothesized that LCZ696 is more effective than valsartan alone in treatment of cardiovascular abnormalities associated with experimental CKD. METHODS AND RESULTS: Male Sprague Dawley rats underwent 5/6 nephrectomy and were subsequently randomized to no treatment (CKD), 30 mg/kg valsartan (VAL), or 60 mg/kg LCZ696 (LCZ)...
January 8, 2018: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/29322980/neurology-of-renal-disorders
#8
Pushpendra N Renjen, Dinesh Chaudhari, Gaurav Sagar, Sanjiv Jasuja
Chronic kidney disease (CKD) is a critical and rapidly growing global health problem. Neurological complications occur in almost all patients with severe CKD, potentially affecting all levels of the nervous system, from the central nervous system (CNS) through to the peripheral nervous system (PNS). Patients with CKD exhibit a high incidence of symptomatic and occult cerebrovascular diseases, associated tremendously high levels of inflammatory factors and homocysteine, as well as anemia, hypertension, and diabetes...
January 2018: Neurology India
https://www.readbyqxmd.com/read/29319771/peritoneal-dialysis-as-the-first-dialysis-treatment-option-initially-unplanned
#9
Marcela Lara Mendes, Camila Albuquerque Alves, Edwa Maria Bucuvic, Dayana Bitencourt Dias, Daniela Ponce
Most patients with stage 5 CKD start RRT of unplanned manner. Unplanned dialysis, also known as urgent start, may be defined as hemodialysis (HD) started without permanent vascular access, i.e., using a central venous catheter (CVC), or as peritoneal dialysis (PD) started within seven days after implantation of the catheter, without family training. Although few studies have evaluated the PD as an immediate treatment option for patients starting urgent RRT, theirs results suggest that it is a feasible and safe alternative, with infectious complications and survival similar to patients treated with unplanned HD...
October 2017: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/29319766/epic-trial-education-programme-impact-on-serum-phosphorous-control-in-ckd-5d-patients-on-hemodialysis
#10
Carmen Tzanno Branco Martins, Bárbara Margareth Menardi Biavo, Clarissa Baia Bargas Uezima, Jacqueline Alves Pereira Dos Santos, Camila Machado de Barros, Elzo Ribeiro Júnior, Paul Clesca Troconis, Cristoforo Scavone, Marcus Vinicius de Souza João Luiz
INTRODUCTION: In stage 5D chronic kidney disease (CKD 5D) patients, the encouragement of treatment adherence by health professionals is a significant clinical challenge. OBJECTIVES: This study evaluates the impact of a nutritional education programme on hyperphosphatemia, utilizing the transtheoretical model of behavior change (TMBC). SUBJECTS AND METHODS: A prospective interventional study comprising 179 CKD 5D patients with hypophosphatemia...
October 2017: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/29318212/timely-referral-to-outpatient-nephrology-care-slows-progression-and-reduces-treatment-costs-of-chronic-kidney-diseases
#11
Gerhard Lonnemann, Johannes Duttlinger, David Hohmann, Lennart Hickstein, Helmut Reichel
Introduction: We present a new approach to evaluate the importance of ambulatory nephrology care in patients with chronic kidney disease (CKD). Methods: An anonymized health claims database of German insurance companies was searched in a retrospective analysis for patients with CKD using the codes of the International Classification of Diseases, 10th German modification. A total of 105,219 patients with CKD were identified. Patients were assigned to the group "timely referral," when nephrology care was present in the starting year 2009, or initiated during the following 3 years in CKD1-4...
March 2017: KI Reports
https://www.readbyqxmd.com/read/29316564/primary-prevention-of-stroke-in-chronic-kidney-disease-patients-a-scientific-update
#12
Stefana Catalina Bilha, Alexandru Burlacu, Dimitrie Siriopol, Luminita Voroneanu, Adrian Covic
BACKGROUND: Although chronic kidney disease (CKD) is an independent risk factor for stroke, official recommendations for the primary prevention of stroke in CKD are generally lacking. SUMMARY: We searched PubMed and ISI Web of Science for randomised controlled trials, observational studies, reviews, meta-analyses and guidelines referring to measures of stroke prevention or to the treatment of stroke-associated risk factors (cardiovascular disease in general and atrial fibrillation (AF), arterial hypertension or carotid artery disease in particular) among the CKD population...
January 9, 2018: Cerebrovascular Diseases
https://www.readbyqxmd.com/read/29316279/bowel-health-in-chronic-kidney-disease-patient-perceptions-differ-from-clinical-definitions
#13
Claire Trimingham, Stephen McDonald, Kathryn Dansie, Shilpa Jesudason, Randall Faull, Phil Clayton, Grace Liew, Richard Le Leu, Anthony Meade
BACKGROUND: The bowel health of those with chronic kidney disease (CKD) can be affected by medications, fluid/dietary allowances, reduced activity and pre-existing medical conditions. Patient perceptions of their bowel health can differ from those of health care professionals and the burden of gastrointestinal symptoms could be inaccurately reported. METHODS: Adults with CKD, including those undergoing haemodialysis, peritoneal dialysis and kidney transplant from four South Australian hospitals enrolled in the study...
January 8, 2018: Journal of Renal Care
https://www.readbyqxmd.com/read/29316062/efficacy-and-safety-of-ombitasvir-paritaprevir-ritonavir-combination-therapy-for-genotype-1b-chronic-hepatitis-c-patients-complicated-with-chronic-kidney-disease
#14
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Tadashi Ikegami, Noritomo Shimada, Keizo Kato, Hiroshi Abe, Tomomi Okubo, Norio Itokawa, Chisa Kondo, Shigeru Mikami, Toru Asano, Yoshimichi Chuganji, Yasushi Matsuzaki, Hidenori Toyoda, Takashi Kumada, Etsuko Iio, Yasuhito Tanaka, Katsuhiko Iwakiri
AIM: The aim of this study was to clarify the effects and safety of ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) therapy in genotype 1b chronic hepatitis C patients with non-dialysis chronic kidney disease (CKD). METHODS: This retrospective, multicenter study of 12-week OBT/PTV/r therapy included genotype 1b patients with non-dialysis CKD. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 . Virologic responses and treatment-emergent adverse events (TEAEs) in patients with CKD were compared with those in patients without CKD...
January 9, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29316051/safety-and-efficacy-of-sofosbuvir-and-ribavirin-for-genotype-2-hepatitis-c-japanese-patients-with-renal-dysfunction
#15
Takuya Sho, Goki Suda, Atsushi Nagasaka, Yoshiya Yamamoto, Ken Furuya, Kenichi Kumagai, Minoru Uebayashi, Katsumi Terashita, Tomoe Kobayashi, Izumi Tsunematsu, Manabu Onodera, Takashi Meguro, Megumi Kimura, Jun Ito, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masatsugu Ohara, Yuji Ono, Masato Nakai, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto
BACKGROUND AND AIM: The safety and efficacy of sofosbuvir and ribavirin have not been well clarified in patients with renal dysfunction because clinical trials did not include such patients. We evaluated the safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C virus (HCV)-infected patients with renal dysfunction. METHODS: The study included genotype 2 HCV-infected patients who received sofosbuvir and ribavirin between July 2014 and May 2017...
January 9, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29314251/clinical-and-hematological-data-to-group-different-chronic-kidney-disease-patients-a-practical-approach-to-establish-different-groups-of-patients
#16
Vinícius B Péterle, Jéssica de O Souza, Fernanda de O Busato, Frederico J Eutrópio, Gisele de A P da Costa, David N Olivieri, Carlos E Tadokoro
BACKGROUND: Chronic kidney disease (CKD) is the convergent point of several pathological processes, and its evolution is insidious and characterized by a progressive and irreversible loss of kidney function. This impaired function induces the accumulation of uremic toxins and individuals with terminal CKD often have altered physiological responses, including a persistent state of immuno-suppression and development of diseases. A better characterization and stratification of these patients with CKD in different immuno-compromised groups would contribute to more effective and personalized treatments...
January 4, 2018: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/29311660/defining-phenotypes-in-diabetic-nephropathy-a-novel-approach-using-a-cross-sectional-analysis-of-a-single-centre-cohort
#17
Rosa M Montero, Athula Herath, Ashfaq Qureshi, Ehsanollah Esfandiari, Charles D Pusey, Andrew H Frankel, Frederick W K Tam
The global increase in Diabetes Mellitus (DM) has led to an increase in DM-Chronic Kidney Disease (DM-CKD). In this cross-sectional observational study we aimed to define phenotypes for patients with DM-CKD that in future may be used to individualise treatment We report 4 DM-CKD phenotypes in 220 patients recruited from Imperial College NHS Trust clinics from 2004-2012. A robust principal component analysis (PCA) was used to statistically determine clusters with phenotypically different patients. 163 patients with complete data sets were analysed: 77 with CKD and 86 with DM-CKD...
January 8, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29307660/vitamin-d-receptor-activation-by-paricalcitol-and-insulin-resistance-in-ckd
#18
B Spoto, P Pizzini, S Cutrupi, G Tripepi, G Curatola, F Mallamaci, C Zoccali
BACKGROUND AND AIMS: The nature of the link (causal vs non-causal) between low 1,25-OH vitamin D and insulin resistance (IR) in patients with chronic kidney disease (CKD) remains elusive. We have now made a post hoc analysis of the effect of vitamin D receptor activation by paricalcitol on IR in the complete dataset of a double-blind, randomized, placebo controlled trial, the Paricalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY). METHODS AND RESULTS: Eighty-eight patients with stage 3-4 CKD were randomized (1:1) to receive 2 μg/day paricalcitol or matching placebo for 12 weeks...
December 7, 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/29305902/effects-of-oral-paricalcitol-therapy-on-arterial-stiffness-and-osteopontin-in-hypertensive-patients-with-chronic-kidney-disease-and-secondary-hyperparathyroidism
#19
Michalis Giakoumis, Costas Tsioufis, Kyriakos Dimitriadis, Makro Sonikian, Alexandros Kasiakogias, Eirini Andrikou, Theodoros Kalos, Dimitrios Konstantinidis, Konstantinos Filis, Dimitrios Petras, Dimitrios Tousoulis
BACKGROUND: Arterial stiffness is linked to the progression of atherosclerosis, while activation of vitamin D receptor exerts favorable cardiovascular effects in patients with renal insufficiency. In this study, we investigated the effects of oral treatment with paricalcitol, a potent vitamin D receptor activator on arterial stiffness and osteopontin, a marker of atherosclerosis, in hypertensive patients with chronic kidney disease (CKD) and secondary hyperparathyroidism. METHODS: We followed up 29 treated hypertensive patients (mean age 74...
January 3, 2018: Hellenic Journal of Cardiology: HJC, Hellēnikē Kardiologikē Epitheōrēsē
https://www.readbyqxmd.com/read/29305402/metformin-treatment-in-patients-with-type-2-diabetes-and-chronic-kidney-disease-stages-3a-3b-or-4
#20
Jean-Daniel Lalau, Farshad Kajbaf, Youssef Bennis, Anne-Sophie Hurtel-Lemaire, Frans Belpaire, Marc E De Broe
OBJECTIVE: This study was conducted to define a safe, effective dose regimen for metformin in moderate and severe chronic kidney disease (CKD; stages 3A/3B and 4, respectively), after the lifting of restrictions on metformin use in patients with diabetes with moderate-to-severe CKD in the absence of prospective safety and efficacy studies. RESEARCH DESIGN AND METHODS: Three complementary studies were performed: 1) a dose-finding study in CKD stages 1-5, in which blood metformin concentrations were evaluated during a 1-week period after each dose increase; 2) a 4-month metformin treatment study for validating the optimal metformin dose as a function of the CKD stage (3A, 3B, and 4), with blood metformin, lactate, and HbA1c concentrations monitored monthly; and 3) an assessment of pharmacokinetic parameters after the administration of a single dose of metformin in steady-state CKD3A, 3B, and 4...
January 5, 2018: Diabetes Care
keyword
keyword
19486
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"